MedTrace Logo

SSRI's and the Rate of Progression From MCI to Dementia

NCT04901494 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-10-11

No results posted yet for this study

Summary

This trial is investigating if serotonin reuptake inhibitor (SSRI) use in Mild Cognitive Impairment (MCI) patients will lead to a lower rate of progression to dementia.

It's hypothesized that patients treated with an SSRI at the time of MCI diagnosis, without evidence of an active primary psychiatric condition other than neurocognitive disorder, will have a lower rate of progression to Alzheimer's disease dementia or to other types of dementia.

Conditions

Interventions

DRUG

SSRI

Selective serotonin reuptake inhibitor

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Principal Investigators

  • Maria Kataki, MD · Ohio State University

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2023-10-06
Completion
2023-10-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04901494 on ClinicalTrials.gov